Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SP16 in Healthy Volunteers
NCT03651089Phase 1Completed
- Sponsor
- Serpin Pharma
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SP16 in acute myocardial infarction (AMI) (4 arms), sponsored by Serpin Pharma. Primary endpoint: Preliminary Safety Assessment: Occurence of adverse events at 7 days. Started Jul 2018; status: completed.
02
Drugs
SP16
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03651089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651089.